Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available.

Trial Profile

Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs IMC 3C5 (Primary)
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Eli Lilly
  • Most Recent Events

    • 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 29 May 2015 Primary endpoint has not been met (maximum tolerated dose (MTD)) according to results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 07 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top